BARDA has funded development of new antibiotics to meet the challenge of increased resistance to drugs currently in use. Last year, Congress incorporated the Generate Antibiotic Incentives Now (GAIN) Act into reauthorization legislation for the FDA. The purpose of this legislation is to extend the exclusivity time for new antibiotics and thereby encourage their development. When these new antibiotics become available, they will provide additional opportunities to reduce flu-related deaths.
The progress made in combating flu is evident in the headlines. Government agencies, scientists and companies are working together to achieve progress in an area that could present a great threat to our nation and its people. The fact that vaccine shortages this season are localized as people rush to get their vaccines and not widespread because of manufacturing issues means they are doing their job to protect us. It also demonstrates that what was once a greatly feared disease appears a lot less frightening to the general public, but only because government planning years ago made it possible.
This work is the opinion of the columnist and in no way reflects the opinion of ABC News.
Steve Brozak is President of WBB Securities, an independent broker-dealer and investment bank specializing in pharmaceutical, biotechnology, medical device research. Henry Bassman and Emad Samad are Managing Directors at WBB Securities.